1don MSN
Eli Lilly Is Dominating the GLP-1 Market: Here's What a $5,000 Investment Could Look Like in 5 Years
The weight loss tailwind isn't about to come to a halt.
Tracking the oral GLP-1 market battle between Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo. (Hase-Hoch-2/iStock/Getty Images Plus) With the recent launches ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results